Symbols / LENZ Stock $9.15 -8.41% LENZ Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
LENZ (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Stock Fundamentals
Scroll to Statements
Market Cap 286.89M Enterprise Value -4.64M Income -82.13M Sales 19.09M Book/sh 9.07 Cash/sh 9.32
Dividend Yield — Payout 0.00% Employees 152 IPO — P/E — Forward P/E -3.02
PEG — P/S 15.03 P/B 1.01 P/C — EV/EBITDA 0.05 EV/Sales -0.24
Quick Ratio 13.91 Current Ratio 14.23 Debt/Eq 0.29 LT Debt/Eq — EPS (ttm) -2.85 EPS next Y -3.03
EPS Growth — Revenue Growth — Earnings 2026-05-06 ROA -21.86% ROE -33.63% ROIC —
Gross Margin 97.81% Oper. Margin -24.22% Profit Margin 0.00% Shs Outstand 31.35M Shs Float 18.48M Short Float 49.54%
Short Ratio 7.79 Short Interest — 52W High 50.40 52W Low 8.25 Beta 2.29 Avg Volume 958.10K
Volume 950.06K Target Price $39.57 Recom Strong_buy Prev Close $9.99 Price $9.15 Change -8.41%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.57
Mean price target
2. Current target
$9.15
Latest analyst target
3. DCF / Fair value
$-23.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.15
Low
$20.00
High
$60.00
Mean
$39.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 main HC Wainwright & Co. Buy → Buy $48
2026-03-26 main Citigroup Buy → Buy $26
2026-03-25 main B of A Securities Buy → Buy $29
2025-10-20 reit Raymond James Outperform → Outperform $50
2025-10-10 main Piper Sandler Overweight → Overweight $67
2025-08-01 main Citigroup Buy → Buy $52
2025-08-01 main HC Wainwright & Co. Buy → Buy $56
2025-07-31 main Citigroup Buy → Buy $49
2025-07-31 main Raymond James Outperform → Outperform $40
2025-07-28 main HC Wainwright & Co. Buy → Buy $48
2025-05-08 reit HC Wainwright & Co. Buy → Buy $38
2025-04-16 reit HC Wainwright & Co. Buy → Buy $38
2025-04-14 main Piper Sandler Overweight → Overweight $51
2025-03-20 main Citigroup Buy → Buy $47
2024-11-07 reit HC Wainwright & Co. Buy → Buy $38
2024-09-27 init Raymond James — → Outperform $37
2024-08-15 main Piper Sandler Overweight → Overweight $36
2024-08-15 reit HC Wainwright & Co. Buy → Buy $38
2024-08-12 init HC Wainwright & Co. — → Buy $38
2024-04-15 init Leerink Partners — → Outperform $32
News
RSS: Latest LENZ news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-27 CHEVALLARD DANIEL R Chief Financial Officer — 7,500 $8.57 $64,275
2026-03-27 SCHIMMELPENNINK EVERT B. Chief Executive Officer — 28,089 $8.95 $251,411
2026-03-27 GEORGE JEFFREY P. Director — 5,592 $8.92 $49,890
2025-11-17 OLSSON SHAWN Officer — 10,000 $25.74 $261,022
2025-11-17 OLSSON SHAWN Officer — 10,000 $2.08 $20,800
2025-11-07 CHEVALLARD DANIEL R Chief Financial Officer — 2,198 $22.71 $50,017
2025-11-07 MCCOLLUM JAMES W Director — 10,500 $22.79 $239,278
2025-09-30 VERSANT VENTURE CAPITAL VI, L.P. Beneficial Owner of more than 10% of a Class of Security — 224,974 $45.35 $10,352,017
2025-09-18 VERSANT VENTURE CAPITAL VI, L.P. Beneficial Owner of more than 10% of a Class of Security — 135,304 $41.59 $5,714,356
2025-08-26 VERSANT VENTURE CAPITAL VI, L.P. Beneficial Owner of more than 10% of a Class of Security — 188,094 $38.97 $7,423,920
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
19.09
0.00
0.00
-100.00%
15.00
Operating Revenue
19.09
0.00
0.00
-100.00%
15.00
Cost Of Revenue
0.42
0.00
—
—
Reconciled Cost Of Revenue
0.42
0.00
—
—
Gross Profit
18.67
0.00
—
—
Operating Expense
109.81
+87.35%
58.61
-19.08%
72.43
+184.22%
25.48
Research And Development
18.67
-37.35%
29.80
-49.92%
59.50
+181.68%
21.12
Selling General And Administration
91.14
+216.35%
28.81
+122.89%
12.93
+196.58%
4.36
Total Expenses
110.23
+88.07%
58.61
-19.08%
72.43
+184.22%
25.48
Operating Income
-91.14
-55.50%
-58.61
+19.08%
-72.43
-590.92%
-10.48
Total Operating Income As Reported
-91.14
-55.50%
-58.61
+19.08%
-72.43
-590.92%
-10.48
EBITDA
-90.85
-55.16%
-58.55
+19.14%
-72.41
-591.30%
-10.47
Normalized EBITDA
-90.85
-55.16%
-58.55
+19.14%
-72.41
-591.30%
-10.47
Reconciled Depreciation
0.29
+394.83%
0.06
+286.67%
0.01
+87.50%
0.01
EBIT
-91.14
-55.50%
-58.61
+19.08%
-72.43
-590.92%
-10.48
Net Income
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Pretax Income
-81.62
-64.01%
-49.77
+29.05%
-70.15
-570.37%
-10.46
Net Non Operating Interest Income Expense
9.76
+14.07%
8.55
+290.73%
2.19
—
Net Interest Income
9.76
+14.07%
8.55
+290.73%
2.19
—
Interest Income Non Operating
9.76
+14.07%
8.55
+290.73%
2.19
—
Interest Income
9.76
+14.07%
8.55
+290.73%
2.19
—
Other Income Expense
-0.24
-184.08%
0.29
+210.75%
0.09
+389.47%
0.02
Other Non Operating Income Expenses
-0.24
-184.08%
0.29
+210.75%
0.09
+389.47%
0.02
Tax Provision
0.50
+50100.00%
0.00
+100.56%
-0.18
-151.59%
0.35
Tax Rate For Calcs
0.00
+0.00%
0.00
+8128.84%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Net Income From Continuing Operation Net Minority Interest
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Net Income From Continuing And Discontinued Operation
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Net Income Continuous Operations
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Normalized Income
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Net Income Common Stockholders
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Diluted EPS
-2.85
-21.79%
-2.34
+14.61%
-2.74
-547.19%
-0.42
Basic EPS
-2.85
-21.79%
-2.34
+14.61%
-2.74
-547.19%
-0.42
Basic Average Shares
28.81
+35.39%
21.28
-16.65%
25.53
+0.00%
25.53
Diluted Average Shares
28.81
+35.39%
21.28
-16.65%
25.53
+0.00%
25.53
Diluted NI Availto Com Stockholders
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Line Item Trend 2024-12-31
Total Assets
215.30
Current Assets
211.92
Cash Cash Equivalents And Short Term Investments
209.03
Cash And Cash Equivalents
20.16
Cash Financial
—
Other Short Term Investments
188.87
Receivables
0.00
Accounts Receivable
0.00
Inventory
0.00
Raw Materials
—
Finished Goods
—
Restricted Cash
0.11
Other Current Assets
2.77
Total Non Current Assets
3.39
Net PPE
1.99
Gross PPE
2.06
Accumulated Depreciation
-0.07
Properties
0.00
Machinery Furniture Equipment
0.62
Other Properties
1.34
Leases
0.10
Non Current Deferred Assets
0.00
Non Current Prepaid Assets
1.40
Other Non Current Assets
1.40
Total Liabilities Net Minority Interest
11.22
Current Liabilities
10.41
Payables And Accrued Expenses
9.84
Payables
4.26
Accounts Payable
4.26
Current Accrued Expenses
5.58
Total Tax Payable
—
Income Tax Payable
—
Current Debt And Capital Lease Obligation
0.57
Current Capital Lease Obligation
0.57
Total Non Current Liabilities Net Minority Interest
0.81
Long Term Debt And Capital Lease Obligation
0.81
Long Term Capital Lease Obligation
0.81
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
204.08
Common Stock Equity
204.08
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
27.53
Ordinary Shares Number
27.52
Treasury Shares Number
0.01
Additional Paid In Capital
348.90
Retained Earnings
-145.01
Gains Losses Not Affecting Retained Earnings
0.20
Other Equity Adjustments
0.20
Total Equity Gross Minority Interest
204.08
Total Capitalization
204.08
Working Capital
201.51
Invested Capital
204.08
Total Debt
1.38
Capital Lease Obligations
1.38
Net Tangible Assets
204.08
Tangible Book Value
204.08
Derivative Product Liabilities
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-69.17
-16.47%
-59.39
+1.64%
-60.38
-1375.92%
-4.09
Cash Flow From Continuing Operating Activities
-69.17
-16.47%
-59.39
+1.64%
-60.38
-1375.92%
-4.09
Net Income From Continuing Operations
-82.13
-65.02%
-49.77
+28.87%
-69.97
-547.19%
-10.81
Depreciation Amortization Depletion
0.29
+394.83%
0.06
+286.67%
0.01
+87.50%
0.01
Depreciation And Amortization
0.29
+394.83%
0.06
+286.67%
0.01
+87.50%
0.01
Stock Based Compensation
12.55
+97.12%
6.37
+373.94%
1.34
+86.27%
0.72
Asset Impairment Charge
0.08
0.00
—
—
Operating Gains Losses
—
1.06
+964.23%
-0.12
-485.71%
-0.02
Gain Loss On Investment Securities
—
1.05
+951.22%
-0.12
-485.71%
-0.02
Gain Loss On Sale Of PPE
0.00
-100.00%
0.02
0.00
—
Change In Working Capital
3.45
+126.35%
-13.09
-239.12%
9.41
+56.52%
6.01
Change In Receivables
-0.33
0.00
—
—
Changes In Account Receivables
-0.33
0.00
—
—
Change In Inventory
-4.28
0.00
—
—
Change In Prepaid Assets
-3.03
-12208.00%
0.03
-96.71%
0.76
+136.03%
-2.11
Change In Payables And Accrued Expense
10.88
+192.73%
-11.74
-235.88%
8.64
+5.96%
8.15
Change In Accrued Expense
10.97
+247.12%
-7.46
-195.85%
7.78
+101.74%
3.86
Change In Payable
-0.09
+97.90%
-4.28
-599.88%
0.86
-80.07%
4.29
Change In Account Payable
-0.09
+97.90%
-4.28
-599.88%
0.86
-80.07%
4.29
Change In Other Current Assets
0.20
+114.23%
-1.38
-13870.00%
0.01
+134.48%
-0.03
Investing Cash Flow
-75.67
+51.02%
-154.48
-421.52%
-29.62
-79956.76%
-0.04
Cash Flow From Continuing Investing Activities
-75.67
+51.02%
-154.48
-421.52%
-29.62
-79956.76%
-0.04
Net PPE Purchase And Sale
-0.83
-76.71%
-0.47
-1460.00%
-0.03
+18.92%
-0.04
Purchase Of PPE
-0.83
-76.71%
-0.47
-1460.00%
-0.03
+18.92%
-0.04
Capital Expenditure
-0.83
-76.71%
-0.47
-1460.00%
-0.03
+18.92%
-0.04
Net Investment Purchase And Sale
-74.84
+51.41%
-154.01
-420.47%
-29.59
—
Purchase Of Investment
-280.80
-16.08%
-241.91
-364.40%
-52.09
—
Sale Of Investment
205.96
+134.31%
87.90
+290.67%
22.50
—
Financing Cash Flow
149.75
-24.75%
199.00
+146.59%
80.70
+166.67%
30.26
Cash Flow From Continuing Financing Activities
149.75
-24.75%
199.00
+146.59%
80.70
+166.67%
30.26
Net Common Stock Issuance
147.75
+85.82%
79.51
0.00
—
Proceeds From Stock Option Exercised
2.00
-50.57%
4.04
+1889.16%
0.20
+57.36%
0.13
Net Other Financing Charges
—
115.45
+4757.16%
-2.48
—
Changes In Cash
4.91
+133.00%
-14.87
-59.85%
-9.30
-135.59%
26.13
Beginning Cash Position
20.27
-42.31%
35.14
-20.93%
44.44
+142.75%
18.31
End Cash Position
25.18
+24.21%
20.27
-42.31%
35.14
-20.93%
44.44
Free Cash Flow
-70.00
-16.94%
-59.86
+0.91%
-60.41
-1363.42%
-4.13
Amortization Of Securities
-3.41
+15.14%
-4.02
-280.04%
-1.06
—
Common Stock Issuance
147.75
+85.82%
79.51
0.00
—
Issuance Of Capital Stock
147.75
+85.82%
79.51
-4.17%
82.98
+175.37%
30.13
Net Preferred Stock Issuance
—
0.00
-100.00%
82.98
+175.37%
30.13
Preferred Stock Issuance
—
0.00
-100.00%
82.98
+175.37%
30.13
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category